Biopharma | 26 June 2026
Moderna outlines aggressive multi-modal growth strategy
The company emphasized that its mRNA system is built on three pillars—mRNA science, delivery science, and manufacturing processes
The company emphasized that its mRNA system is built on three pillars—mRNA science, delivery science, and manufacturing processes
Acquisition strengthens Merck's life sciences portfolio, expands capabilities across research and biopharma manufacturing
This makes the company among few in India to offer fully integrated, end-to-end ADC drug substance development and manufacturing, encompassing payload synthesis, linker development and manufacturing
Partnership with Duopharma Biotech covers human insulin, insulin glargine and insulin aspart, supporting diabetes care and medicine security in Malaysia
New digital platform provides global sponsors with live visibility into R&D, process development and GMP manufacturing operations, enhancing collaboration and decision-making
Under the agreement, Apogee shareholders will receive $135.11 per share in cash, and the transaction has been unanimously approved by both companies’ boards
Researchers emphasized that the benefit persisted well beyond the treatment period, reinforcing the clinical rationale for time-limited therapy in selected patients
M&A activity, IPOs and late-stage investments gain momentum as investors prioritize clinical validation, while early-stage biotech firms continue to face funding challenges
The event is expected to bring together health and wellness enthusiasts for an afternoon of insights, learning and practical takeaways
New Tracxn report highlights growing investor confidence in automated cell therapy production, with Cellares and Ori Biotech dominating funding and regulatory milestones
Findings show growing optimism across the pharma sector as dealmaking accelerates, innovation strengthens, and companies adapt to tariffs, pricing reforms, and looming patent expirations
MabionCD20 is a monoclonal antibody originally developed by Mabion as a biosimilar candidate to MabThera and Rituxan therapies
Phase 1 study to evaluate Siglec-6-targeted CAR-T therapy in relapsed or refractory AML and CLL patients, marking a major milestone for T-CURX’s scalable non-viral CAR-T platform
New hit discovery service combines integrated DNA-Encoded Library screening, structural biology, biophysics, and X-ray crystallography
The graduating cohort comprised seven batches across five specialized programs
Independent DSMB recommends continuation of Masupirdine without modifications as enrollment reaches 88% in global trial
MSD joins as anchor customer as Aurobindo strengthens its position in the fast-growing global biologics manufacturing market
Teva said the launch strengthens its biosimilars strategy and expands access to biologic medicines across Europe
Anti-GD2 monoclonal antibody for high-risk neuroblastoma advances toward BLA submission following successful tech transfer from California to Bengaluru
Madhav Bhutada says overdependence on large CDMOs and delayed engagement can increase development costs by up to 40% and slow clinical progress
Subscribe To Our Newsletter & Stay Updated
